Polypharmacotherapeutic and ethnopharmacological medication for Alzheimer’s disease

Bandara Gamini
Pharmaceutical Research, USA

There is no cure for Alzheimer’s disease (AD); clinical trials have all failed. Therefore, it is an irrefutable necessity, the fundamental reevaluation of AD treatment R&D. A viable alternate approach is polypharmacotherapeutic & ethnopharmacological solution. Ethnopharmacology is the precursor to numerous modern medicines. Polypharmacotherapy is practiced in many disease treatment regimes. The proposed therapy addresses all four AD etiological factors: amyloid plaques, neurofibrillary (tau) tangles, brain cell dysfunction, and neurotoxicity. Institutional reticence has to be overcome to implement the proposed novel AD therapy. The critical need is genuinely address the looming epidemic of AD, with the proposed ethnopharmacological and polypharmacotherapeutic approach.

Biography

Bandara Gamini had his medical education at the Louisiana State University and electronics education at the Eastern Illinois University. He heads a private company, Pharmaceutical Research, in Lafayette, Louisiana after a two-decade professorship at the University of Louisiana, Lafayette, Louisiana.

DrG@gamini.us